Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants

Vaccine

Volumn 23, Issue 43, 2005, Pages 5106-5112

  Tapiainen, Terhi ^a,b   Cherry, James D ^c   Heininger, Ulrich ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b UNIVERSITY OF OULU   (Finland)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Immunogenicity; Injection site; Pertussis vaccine; Reactogenicity

Indexed keywords

ANTIBODY; BACTERIAL ANTIGEN; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEMAGGLUTININ; PERTACTIN; PERTUSSIS VACCINE;

ANOREXIA; ARTICLE; BORDETELLA PERTUSSIS; BUTTOCK; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYING; DROWSINESS; DRUG ACTIVITY; DRUG EFFECT; DRUG FORMULATION; ERYTHEMA; FEMALE; FEVER; GEOMETRY; HUMAN; IMMUNOGENICITY; INFANCY; INFANT; INFECTION PREVENTION; INJECTION SITE; IRRITABILITY; MALE; NORMAL HUMAN; PERTUSSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; SIDE EFFECT; SKIN INDURATION; SYSTEMIC DISEASE; THIGH;

ANTIBODIES, BACTERIAL; BORDETELLA PERTUSSIS; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DRUG EVALUATION; HUMANS; INFANT; PERTUSSIS VACCINE; WHOOPING COUGH;

EID: 24944566762     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.05.039     Document Type: Article

References (20)

1. F.H. Gilles, and J.H. French Postinjection sciatic nerve palsies in infants and children J Pediatr 58 1961 195 204
2. L.J. Baraff, C.L. Cody, and J.D. Cherry DTP-associated reactions: an analysis by injection site, manufacturer, prior reactions, and dose Pediatrics 73 1984 31 36
3. A.E. Tozzi, M.L. Ciofi degli Atti, S.G. Wassilak, S. Salmaso, P. Panei, and A. Anemona Predictors of adverse events after the administration of acellular and whole-cell diphtheria-tetanus-pertussis vaccines Vaccine 16 1998 320 322
4. I.F. Cook, and J. Murtagh Comparative reactogenicity and parental acceptability of pertussis vaccines administered into the ventrogluteal area and anterolateral thigh in children aged 2, 4, 6 and 18 months Vaccine 21 2003 3330 3334
5. F.E. Shaw Jr., H.A. Guess, J.M. Roets, F.E. Mohr, P.J. Coleman, and E.J. Mandel Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination Vaccine 7 1989 425 430
6. D.B. Fishbein, L.A. Sawyer, F.L. Reid-Sanden, and E.H. Weir Administration of human diploid-cell rabies vaccine in the gluteal area N Engl J Med 318 1988 124 125
7. K. Stehr, J.D. Cherry, and U. Heininger A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine Pediatrics 101 1998 1 11
8. U. Heininger, J.D. Cherry, P.D. Christenson, M. Überall, S. Laussucq, and T. Eckhardt Comparative study of Lederle/Takeda acellular and Lederle whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants in Germany Vaccine 12 1994 81 86
9. M.A. Überall, K. Stehr, J.D. Cherry, U. Heininger, S. Schmitt-Grohe, and S. Laussucq Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group Dev Biol Stand 89 1997 83 89
10. S. Schmitt-Grohe, K. Stehr, J.D. Cherry, U. Heininger, M. Überall, and S. Laussucq Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group Dev Biol Stand 89 1997 113 118
11. K. Miyamura, S. Nishio, A. Ito, R. Murata, and R. Kono Micro cell culture method for determination of diphtheria toxin and antitoxin titres using VERO cells. I. Studies on factors affecting the toxin and antitoxin titration J Biol Stand 2 1974 189 201
12. Minimal requirement: tetanus toxoid 4r. Bethesda, MD: National Institutes of Health; 15 December 1952.
13. J.D. Cherry, J. Gornbein, U. Heininger, and K. Stehr A search for serologic correlates of immunity to Bordetella pertussis cough illnesses Vaccine 16 1998 1901 1906
14. M.M. Ipp, R. Gold, M. Goldbach, D.C. Maresky, N. Saunders, and S. Greenberg Adverse reactions to diphtheria, tetanus, pertussis-polio vaccination at 18 months of age: effect of injection site and needle length Pediatrics 83 1989 679 682
15. D. Scheifele, G. Bjornson, L. Barreto, W. Meekison, and R. Guasparini Controlled trial of Haemophilus influenzae type B diphtheria toxoid conjugate combined with diphtheria, tetanus and pertussis vaccines, in 18-month-old children, including comparison of arm versus thigh injection Vaccine 10 1992 455 460
16. P.S. Bergeson, S.A. Singer, and A.M. Kaplan Intramuscular injections in children Pediatrics 70 1982 944 948
17. J. Groswasser, A. Kahn, B. Bouche, S. Hanquinet, N. Perlmuter, and L. Hessel Needle length and injection technique for efficient intramuscular vaccine delivery in infants and children evaluated through an ultrasonographic determination of subcutaneous and muscle layer thickness Pediatrics 100 1997 400 403
18. L.J. Baraff, C.R. Manclark, J.D. Cherry, P. Christenson, and S.M. Marcy Analyses of adverse reactions to diphtheria and tetanus toxoids and pertussis vaccine by vaccine lot, endotoxin content, pertussis vaccine potency and percentage of mouse weight gain Pediatr Infect Dis J 8 1989 502 507
19. J. Storsaeter, H.O. Hallander, L. Gustafsson, and P. Olin Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis Vaccine 16 1998 1907 1916
20. J.F. Hick, J.W. Charboneau, D.M. Brakke, and B. Goergen Optimum needle length for diphtheria-tetanus-pertussis inoculation of infants Pediatrics 84 1989 136 137